AlphAIalphai — Financial news for AI agents
fool.comAUG 202 min read$KPTI

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm (KPTI) reported Q2 2026 revenue of $33.4M, down from $37.9M YoY due to expired agreements. U.S. XPOVIO revenue rose to $30.8M. Net loss was $67M, including non-cash expenses. The company faces a $15.8M debt payment in September, risking a liquidity covenant breach. Management reaffirmed full-year revenue guidance of $130M-$150M and plans to submit an sNDA for selinexor in myelofibrosis.

Original reporting
fool.com
Published Aug 20, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 3:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$KPTIBearishMed
01

Why it matters

The earnings miss and liquidity concerns may trigger short‑term selling, but the reaffirmed guidance and pipeline progress provide a counterbalance.

02

Market read

The release is material for investors tracking cash‑burn biotech stocks and could influence short‑term price action in the sector.

03

What to watch

Potential upside from upcoming sNDA filing and priority review request for myelofibrosis could catalyze a rebound.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Karyopharm Therapeutics reported Q2 2026 results, highlighting a decline in total revenue, a large net loss, and a critical debt covenant deadline in September.

Company-level read

Ticker impact

$KPTIBearishMedium confidence
Context

Q2 2026 earnings released with revenue decline, net loss of $67M, reaffirmed full-year guidance and highlighted debt covenant risk.

Expected impact

Potential short-term downside to $5‑$6 range, with volatility on debt‑refinancing news.

Evidence & confidence

Revenue fell YoY, large net loss and looming $15.8M debt payment create downside pressure; however, guidance reaffirmation and myelofibrosis pipeline progress limit the fall.

Market effects

Sector

Biotech sector may see heightened scrutiny on cash‑burn and debt covenants after this release.

Regional

U.S. biotech stocks could experience modest pullback in early trading.

Global

Limited; primarily affects U.S. listed biotech investors.

Counterpoint

What could challenge this read

The reaffirmed revenue guidance and myelofibrosis pipeline could be undervalued, presenting a buying opportunity on dip.

Key entities

  • Company
    Karyopharm Therapeutics Inc.

    Biopharma focused on selinexor combinations for hematologic cancers.

  • Executive
    Richard Paulson

    CEO who discussed trial failures and pipeline focus.

Read at source← All news

Related articles

AUG 21
$KPTIHighAI 8/10

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

Karyopharm Therapeutics (KPTI) reported Q2 earnings, highlighting a potential FDA accelerated approval for its myelofibrosis combination therapy, while also facing a cash crunch with funds lasting only until September. The company's selinexor and ruxolitinib combination showed promising results, but a $15.8 million loan payment due soon could trigger a default if not addressed. Karyopharm is exploring financing options and strategic alternatives.

insidermonkey.com3 min
AUG 13
$KPTIHighAI 9/10

It's crunch time for Karyopharm as company faces potential default next month

Karyopharm Therapeutics reported Q2 results showing a $67 million loss and cash reserves of $65.4 million. A $15.8 million loan payment is due Sept. 10, and without financing or a waiver the company says it would breach a $10.0 million liquidity covenant and could default. It is negotiating with lenders and pursuing Xpovio label expansion; Q2 Xpovio sales were $30.8 million.

fiercepharma.com6 min
AUG 13
$KPTIMed

Karyopharm Therapeutics Inc. (KPTI): Results of Operations and Financial Condition

Karyopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission – Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Rema

SEC EDGAR 8-K6 min
JUL 31
$KPTIHighAI 9/10

Karyopharm Therapeutics Stock Tanks 68%

Karyopharm Therapeutics Inc. (KPTI) shares fell about 68% after the company reported topline results from its Phase 3 XPORT-EC-042 trial. The trial did not meet its primary endpoint of progression-free survival. The stock dropped 68.17% to $2.2350 on Nasdaq from $7.01 prior close.

rttnews.com2 min